Meeder Asset Management Inc Ardelyx, Inc. Transaction History

Meeder Asset Management Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 02, 2020	SELL	$5.25 - $7.08 $32,901 - $44,370	-6,267 Closed	0 $0
Q2 2020 Aug 11, 2020	SELL	$5.37 - $8.11 $4,553 - $6,877	-848 Reduced 11.92%	6,267 $45,000
Q1 2020 May 15, 2020	BUY	$4.35 - $8.79 $635 - $1,283	146 Added 2.09%	7,115 $40,000
Q4 2019 Feb 13, 2020	BUY	$4.23 - $8.29 $8,899 - $17,442	2,104 Added 43.25%	6,969 $52,000
Q3 2019 Oct 17, 2019	BUY	$2.15 - $6.28 $10,459 - $30,552	4,865 New	4,865 $23,000
Q2 2019 Aug 05, 2019	SELL	$2.49 - $3.73 $2,686 - $4,024	-1,079 Closed	0 $0
Q1 2019 Apr 16, 2019	SELL	$1.88 - $3.35 $1,379 - $2,458	-734 Reduced 40.49%	1,079 $3,000
Q4 2018 Jan 17, 2019	SELL	$1.66 - $4.16 $1,318 - $3,303	-794 Reduced 30.46%	1,813 $3,000
Q3 2018 Nov 02, 2018	BUY	$3.75 - $4.65 $7,387 - $9,160	1,970 Added 309.26%	2,607 $0
Q2 2018 Jul 24, 2018	BUY	$3.7 - $5.8 $370 - $580	100 Added 18.62%	637 $0
Q1 2018 May 03, 2018	BUY	$5.05 - $7.9 $1,212 - $1,896	240 Added 80.81%	537 $3,000
Q4 2017 Feb 02, 2018	BUY	$4.85 - $7.8 $548 - $881	113 Added 61.41%	297 $2,000
Q3 2017 Oct 20, 2017	BUY	$4.35 - $5.7 $800 - $1,048	184	184 $1,000

218

141M

1.08M

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $725M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.